Abstract
We present a sarcoma patient with a tumor reduction of more than 50% in lung metastasis after 2 single courses of the investigational medical product Lutathera (177Lu-DOTA0-Tyr3-octreotate). She was resistant to more than 6 lines of therapy including all the available active drugs in soft tissue sarcomas. The high expression of somatostatin receptors was shown by microarrays and Octreoscan. The overall duration of response exceeded 1 year.
Key Words: microarray expression, Octreoscan, peptide receptor radionuclide therapy, radiolabeled somatostatin analogs, sarcoma, somatostatin receptors, synovial sarcoma
Footnotes
Conflicts of interest and sources of funding: none declared.
REFERENCES
- 1.Florio T, Montella L, Corsaro A, et al. In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors. Anticancer Res. 2003;23:2465–2471. [PubMed] [Google Scholar]
- 2.Rebollo J, Sureda M, Martinez EM, et al. Gene expression profiling of tumors from heavily pretreated patients with metastatic cancer for the selection of therapy: a pilot study. Am J Clin Oncol. 2014. [Epub ahead of print]. [DOI] [PubMed] [Google Scholar]
- 3.Friedberg JW, Van den Abbeele AD, Kehoe K, et al. Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. Cancer. 1999;86:1621–1627. [DOI] [PubMed] [Google Scholar]
- 4.Giannakenas C, Kalofonos HP, Apostolopoulos D, et al. Scintigraphic imaging of sarcomatous tumors with [(111)In-DTPA-Phe-1]-octreotide. Oncology. 2000;58:18–24. [DOI] [PubMed] [Google Scholar]
- 5.Kwekkeboom DJ, De Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–2130. [DOI] [PubMed] [Google Scholar]
- 6.Teunissen J, Kwekkeboom D, Krenning E. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Clin Oncol. 2004;22:2724–2729. [DOI] [PubMed] [Google Scholar]
- 7.Bodei L, Cremonesi M, Grana CM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–2135. [DOI] [PubMed] [Google Scholar]
- 8.Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19. [DOI] [PubMed] [Google Scholar]
- 9.Garkavij M, Nickel M, Sjögreen-Gleisner K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116:1084–1092. [DOI] [PubMed] [Google Scholar]